Amsterdam, Netherlands – Philips has announced that no medical devices will be recalled or removed from the market following a recent device correction advisory. The company, a global leader in health technology, responded promptly to an identified software configuration issue by advising customers to adhere to specific instructions outlined in an Urgent Medical Device Correction notice.
The concern primarily involves heart-monitoring devices, part of a portfolio that Philips expanded after acquiring BioTelemetry, a Pennsylvania-based company, for $2.8 billion. This acquisition, finalized in February 2021, added significant capabilities to Philips’s cardiac diagnostics and monitoring technologies, further enhancing their position in healthcare technology.
Under the latest guidance, customers using affected devices have been advised to consult the correction notice carefully. There is not a need to return any devices. Philips emphasized the importance of reprocessing electrocardiogram data if necessary. Updated ECG reports will be sent out to customers via email after reprocessing is completed, ensuring that any new cardiac events are properly documented and communicated to healthcare providers.
Healthcare professionals have been entrusted with the responsibility to inform patients of any potential impacts from this issue as Philips has stated they will not communicate with patients directly. This approach ensures that information relayed about the use of affected devices is both accurate and within the purview of those managing patient care directly.
In a recent statement from Philips, the company emphasized that maintaining patient safety remains their highest priority as they proceed to address the software configuration issue. “We acted quickly upon detecting post-market signals,” said a Philips spokesperson, “and we have already seen our systems operating normally after implementing the required corrections.” Philips confirmed their ongoing commitment to delivering high-quality care by thoroughly verifying and enhancing their quality control processes across the board.
The commitment extends into a broad, multi-year quality assurance program, reflecting Philips’s long-term approach to ensure reliability and safety in all its healthcare products. This initiative underscores a proactive stance toward post-market surveillance and device integrity, aiming to preemptively manage any potential issues before they affect patient care.
As the situation develops, Philips continues to work in close coordination with healthcare providers and regulatory authorities to ensure all measures taken align with the latest safety standards and contribute effectively to patient health and security. The swift identification and correction of the software issue not only demonstrate Philips’s adherence to rigorous safety protocols but also reinforce the company’s dedication to sustaining trust and reliability in its advanced medical technologies.